ClinicalTrials.gg
Enrolling by invitationNCT04869813SUSIEUpdated Sep 28, 2026

Sarcopenia Magnetic Resonance Imaging Evaluation (SUSIE)

An observational study in Sarcopenia, sponsored by The Cleveland Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by The Cleveland Clinic · Observational

Updated Sep 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Sarcopenia with a site in United States — 37 open to participants now, 47 under way, 1 of them phase 3. Sarcopenia · United States.

Planned enrollment
20th of 40
70 · median 70
Started
2021
with 9 others
Observational
40 of 187
9 open now
Primary completion
2027-01
later than 23 of 46 live
Registered
132nd of 187
by date
Lead sponsor
5 of 187
The Cleveland Clinic

Among the 187 studies in Sarcopenia with a site in United States, this one is the 20th largest by planned enrollment of the 40 observational ones that give a count, is one of 10 that started in 2021, is one of 40 observational ones, reaches primary completion later than 23 of the 46 other live ones, and was the 132nd registered.

Sarcopenia

1,330 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

37 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Sarcopenia with a site in United States, or all of them as a file.
02

Study summary

The goal of the proposed research is to investigate Magnetic Resonance (MR) Fingerprinting and P-MRS (Phosphorus-31 MR Spectroscopy) imaging for characterization of skeletal muscle in heart failure patients with sarcopenia. Heart failure patients with and without sarcopenia will be scanned using MR Fingerprinting and an existing Post-exercise phosphocreatine (PCr) recovery MR imaging protocol to obtain characteristic profiles of quantitative T1, T2, and PCr recovery rate.

Read the detailed description

Sarcopenia is a common comorbidity and predictor of mortality in heart failure that is characterized by a loss of muscle mass and functional strength. Sarcopenia, in heart failure and other chronic diseases, has been consistently predictive of poor outcomes. However, current tools to identify the presence of sarcopenia, such as functional tests and questionnaires are indirect, non-specific, and not effective until patients have reached an overtly cachectic state and significant muscle deterioration has already occurred. MRI can serve an important, noninvasive role in the assessment and management of sarcopenia by providing insight as to tissue microstructure and mitochondrial function. For example, MRI has shown significant changes in T2 relaxation time, diffusion fractional anisotropy, and lipid content in skeletal muscle of pre-frail/frail patients as compared to healthy volunteers. Post-exercise phosphocreatine (PCr) recovery, evaluated using phosphorus-31 (P) MR spectroscopy Imaging(P-MRSI), has shown impairment of mitochondrial function in pre-frail elderly as compared to active elderly. MR fingerprinting (MRF) is a promising tool for tissue characterization via rapid, robust quantification of T1 and T2 relaxation and has been shown to be accurate and reproducible across sites. Despite applications in neuroimaging and cardiac imaging, MRF has had limited use in musculoskeletal imaging and has not been investigated for use in characterizing sarcopenia. Similarly, P-MRS imaging has not been employed for evaluation of sarcopenia in heart failure patients, a population which may have a unique etiology from other sarcopenia phenotypes. Characterization of sarcopenia may support a range of rapidly developing treatment options in this population. While evidence suggests exercise therapy can improve frailty status, for instance in 39% of patients at 12 month follow-up, it is not yet well-understood which patients will respond to treatment. With a range of treatment options such as nutritional supplementation, hormone therapy, and cardiovascular drugs, MRF and P-MRSI could serve as powerful noninvasive tools to provide a personalized approach for sarcopenic phenotypes, match them to appropriate therapy, and monitor therapeutic response.

03

Conditions studied

  • Sarcopenia

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Heart Failure and Healthy volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heart failure patients

    • Age ≥40 yrs
    • Stable chronic heart failure
    • Systolic dysfunction determined by cardiac MRI with left ventricle 40% or less
  • Healthy Volunteers

    • Age ≥40 yrs
    • No diagnosed heart failure or sarcopenia

Exclusion criteria

Exclusion Criteria:

  • Heart failure patients

    • Advanced liver disease, advanced cancer, advanced
  • Healthy volunteers (controls)

    • Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease
    • to MRI Contraindications to MRI
    • Heart pacemaker/defibrillator
    • Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires
    • Cochlear implant or other ear implants
    • Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)
    • Programmable shunt
    • Aneurysm clips and coils
    • Stents
    • Filters (for example, blood clot filters)
    • Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Heart failure patients

    Inclusion criteria: * Age \> or = 40 yrs * Stable chronic heart failure * Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less Exclusion criteria: • Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease Contraindications to MRI such as: * Heart pacemaker/defibrillator * Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires * Cochlear implant or other ear implants * Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity) * Programmable shunt * Aneurysm clips and coils * Stents • Filters (for example, blood clot filters) * Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)

  • Healthy volunteers (Controls)

    Inclusion criteria: * Age \> or = 40 yrs * No diagnosed heart failure or sarcopenia Exclusion criteria • Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease Contraindications to MRI such as: * Heart pacemaker/defibrillator * Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires * Cochlear implant or other ear implants * Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity) * Programmable shunt * Aneurysm clips and coils * Stents * Filters (for example, blood clot filters) * Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)

06

What researchers measure

Primary outcomes

  1. Anticipated Results

    This proposal is expected to produce information as to the change in T1, T2, muscle area, fat fraction, and PCr recovery rate values for heart failure patients with sarcopenia as compared to non-sarcopenic volunteers. Future work will expand upon this study to evaluate to progression of sarcopenia, and evaluate the prognostic value of imaging biomarkers (T1, T2, muscle area, fat fraction, PCr recovery) in predicting heart failure and sarcopenic related outcomes.

    Time frame: 3 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Jan 2027, 69 months after the start.

Of 191 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 69 months is above that.

Counting every sponsor, half of 193 studies reached it within 26 months; a quarter within 12 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jul 2026 → Jan 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2021
First posted
May 3, 2021
StartActual
Apr 9, 2021
Primary completionEst.
Jan 31, 2027was Jul 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Jan 31, 2027
Sep 28, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion Jul 31, 2026→Jan 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04869813
Responsible party
Wilson Tang (Staff Cardiovascular and Metabolic Sciences, The Cleveland Clinic) — Principal investigator
First posted
May 3, 2021
Start date
Apr 9, 2021
Primary completion
Jan 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

W. H. Wilson Tang, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion